Kymriah® is indicated for the treatment of paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse, and adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Preview or download our range of resources specifically designed to help Healthcare Professionals manage patients that have been prescribed with Kymriah.
This page is intended for healthcare professionals. Please do not direct patients to this page.
Please note that these resources are designed for optimal use on desktop or tablet. Functionality may be restricted on some devices, including mobile.
MANAGEMENT GUIDE
This guide provides detailed information about the management of a patient whilst on Kymriah.
HCP TRAINING SLIDES
These training slides provide guidance on when and how to initiate treatment, as well as how to monitor patients successful on treatment.
PHARMACY CELL LAB INFUSION CENTRE TRAINING
Guidance on reception storage, handling, thawing, preparation for infusion of Kymriah to mitigate a decrease in cell viability.
PATIENT AND CAREGIVERS EDUCATIONAL MATERIAL
Guidance for patients who have been prescribed with Kymriah, and their caregivers, on what to expect with their treatment and important supporting information.
PATIENT ALERT CARD
An alert card to help improve communication and continuity of care between patients and their treating doctor.
CAR-T, chimeric antigen receptors cell therapy; HCP, healthcare professional.
Reference
- Kymriah Summary of Product Characteristics; Novartis Pharmaceuticals UK Ltd.
